𝔖 Bobbio Scriptorium
✦   LIBER   ✦

From Darkness to Light With Biomarkers in Early Clinical Trials of Cancer Drugs

✍ Scribed by Carden, CP; Banerji, U; Kaye, SB; Workman, P; de Bono, JS

Book ID
109845559
Publisher
Nature Publishing Group
Year
2009
Tongue
English
Weight
122 KB
Volume
85
Category
Article
ISSN
0009-9236

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Summary of aromatase inhibitor clinical
Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer
✍ Aman U. Buzdar; R. Charles Coombes; Paul E. Goss; Eric P. Winer πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 115 KB

Five years of adjuvant therapy with tamoxifen was considered the gold-standard treatment for postmenopausal women with estrogen receptor-positive breast cancer for many years. Data from a core group of clinical trials investigating the safety and efficacy of aromatase inhibitors (AIs) have challenge

Breast cancer adjuvant chemotherapy dosi
Breast cancer adjuvant chemotherapy dosing in obese patients : Dissemination of information from clinical trials to clinical practice
✍ Christopher G. Greenman; Christina H. Jagielski; Jennifer J. Griggs πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 143 KB

## Abstract ## BACKGROUND Substantial variation in adjuvant breast cancer chemotherapy dosing in obese women suggests that there is uncertainty about optimal practices. The purpose of this study was to investigate variations in dose determinations in clinical trial protocols and publications over